IDEAS home Printed from https://ideas.repec.org/a/eee/hepoli/v79y2006i2-3p337-344.html
   My bibliography  Save this article

The costs and benefits of regulations for reimbursement of new drugs

Author

Listed:
  • Lundkvist, Jonas
  • Jonsson, Bengt
  • Rehnberg, Clas

Abstract

No abstract is available for this item.

Suggested Citation

  • Lundkvist, Jonas & Jonsson, Bengt & Rehnberg, Clas, 2006. "The costs and benefits of regulations for reimbursement of new drugs," Health Policy, Elsevier, vol. 79(2-3), pages 337-344, December.
    • Handle: RePEc:eee:hepoli:v:79:y:2006:i:2-3:p:337-344
    as

    Download full text from publisher

    File URL: http://www.sciencedirect.com/science/article/pii/S0168-8510(06)00031-5
    Download Restriction: Full text for ScienceDirect subscribers only
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Robert W. Hahn, 1998. "Policy Watch: Government Analysis of the Benefits and Costs of Regulation," Journal of Economic Perspectives, American Economic Association, vol. 12(4), pages 201-210, Fall.
    2. Drummond, Michael & Jonsson, Bengt & Rutten, Frans, 1997. "The role of economic evaluation in the pricing and reimbursement of medicines," Health Policy, Elsevier, vol. 40(3), pages 199-215, June.
    3. Boyka Stoykova & Michael Drummond & Marco Barbieri & Jos Kleijnen, 2003. "The lag between effectiveness and cost-effectiveness evidence of new drugs," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 4(4), pages 313-318, December.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Garattini, Livio & Cornago, Dante & De Compadri, Paola, 2007. "Pricing and reimbursement of in-patent drugs in seven European countries: A comparative analysis," Health Policy, Elsevier, vol. 82(3), pages 330-339, August.
    2. Mackenzie Mills, 2023. "HTA Barriers for Conditional Approval Drugs," PharmacoEconomics, Springer, vol. 41(5), pages 529-545, May.
    3. Burapadaja, Siriporn & Kawasaki, Naohito & Charumanee, Suporn & Ogata, Fumihiko, 2007. "Effects of essential medicines on cardiovascular products available for the market in Thailand," Health Policy, Elsevier, vol. 84(1), pages 67-74, November.
    4. Fischer, Katharina Elisabeth, 2012. "A systematic review of coverage decision-making on health technologies—Evidence from the real world," Health Policy, Elsevier, vol. 107(2), pages 218-230.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Matthias Finger & Rolf W. Künneke (ed.), 2011. "International Handbook of Network Industries," Books, Edward Elgar Publishing, number 12961.
    2. Mak, James & Sheehey, Christopher & Toriki, Shannon, 2010. "The passenger vessel services act and America's cruise tourism industry," Research in Transportation Economics, Elsevier, vol. 26(1), pages 18-26.
    3. Kirkpatrick, Colin & Parker, David, 2004. "Regulation and the Privatisation of Water Services in Developing Countries: Assessing the Impact of the General Agreement on Trade in Services (GATS)," Centre on Regulation and Competition (CRC) Working papers 30600, University of Manchester, Institute for Development Policy and Management (IDPM).
    4. Wallace E. Oates & Paul R. Portney & Wallace E. Oates & Paul R. Portney, 2004. "The Political Economy of Environmental Policy," Chapters, in: Environmental Policy and Fiscal Federalism, chapter 1, pages 3-30, Edward Elgar Publishing.
    5. Henschke, Cornelia & Sundmacher, Leonie & Busse, Reinhard, 2013. "Structural changes in the German pharmaceutical market: Price setting mechanisms based on the early benefit evaluation," Health Policy, Elsevier, vol. 109(3), pages 263-269.
    6. Hindrik Vondeling & Peter Iversen, 2004. "Reimbursement of glitazones in treatment of type 2 diabetes patients in Denmark in the context of a voluntary system for submitting pharmacoeconomic studies," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 5(3), pages 263-269, September.
    7. Michael Drummond & Adrian Towse, 2019. "Is rate of return pricing a useful approach when value-based pricing is not appropriate?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(7), pages 945-948, September.
    8. Lee, D. B., 2000. "Methods for evaluation of transportation projects in the USA," Transport Policy, Elsevier, vol. 7(1), pages 41-50, January.
    9. Jackie Krafft & Evens Salies, 2008. "Why and how should innovative industries with high consumer switching costs be re-regulated?," Documents de Travail de l'OFCE 2008-04, Observatoire Francais des Conjonctures Economiques (OFCE).
    10. David B. Evans & Dan Chisholm & Tessa Tan-Torres Edejer, 2012. "Generalized Cost-effectiveness Analysis: Principles and Practice," Chapters, in: Andrew M. Jones (ed.), The Elgar Companion to Health Economics, Second Edition, chapter 48, Edward Elgar Publishing.
    11. Lopez-Casasnovas, Guillem & Puig-Junoy, Jaume, 2000. "Review of the literature on reference pricing," Health Policy, Elsevier, vol. 54(2), pages 87-123, November.
    12. Sumit K. MAJUMDAR, 2014. "Regulation And Job Creation: An Analysis Of Institutional Change And Its Consequences," Annals of Public and Cooperative Economics, Wiley Blackwell, vol. 85(2), pages 305-325, June.
    13. Lenka Gregorová & Milan Žák, 2008. "Byrokratická bariéra kvality regulace [Bureaucratic constraint of the quality of regulation]," Politická ekonomie, Prague University of Economics and Business, vol. 2008(2), pages 196-228.
    14. Andersson, Karolina & Petzold, Max Gustav & Sonesson, Christian & Lonnroth, Knut & Carlsten, Anders, 2006. "Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures?: Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986-2002," Health Policy, Elsevier, vol. 79(2-3), pages 231-243, December.
    15. Gunnar Prause & Eunice Omolola Olaniyi, 2019. "A compliance cost analysis of the SECA regulation in the Baltic Sea," Entrepreneurship and Sustainability Issues, VsI Entrepreneurship and Sustainability Center, vol. 6(4), pages 1907-1921, June.
    16. Syed Mohiuddin, 2014. "A Systematic and Critical Review of Model-Based Economic Evaluations of Pharmacotherapeutics in Patients with Bipolar Disorder," Applied Health Economics and Health Policy, Springer, vol. 12(4), pages 359-372, August.
    17. Anthony Harris & Jing Jing Li & Karen Yong, 2016. "What Can We Expect from Value-Based Funding of Medicines? A Retrospective Study," PharmacoEconomics, Springer, vol. 34(4), pages 393-402, April.
    18. Parker, David, 2001. "Economic Regulation: A Preliminary Literature Review and Summary of Research Questions Arising," Centre on Regulation and Competition (CRC) Working papers 30616, University of Manchester, Institute for Development Policy and Management (IDPM).
    19. Johan Polder & Willem Meerding & Luc Bonneux & Paul Maas, 2005. "A cross-national perspective on cost of illness," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 6(3), pages 223-232, September.
    20. Hugh S.E. Gravelle, 1998. "Ex post Value Reimbursement for Pharmaceuticals," Medical Decision Making, , vol. 18(2_suppl), pages 27-38, April.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:hepoli:v:79:y:2006:i:2-3:p:337-344. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu or the person in charge (email available below). General contact details of provider: http://www.elsevier.com/locate/healthpol .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.